Cancer statistics, CA Cancer J Clin, vol.59, pp.225-274, 2009. ,
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions, Clin Adv Hematol Oncol HO, vol.11, pp.14-23, 2013. ,
The natural history of metastatic progression in men with prostatespecific antigen recurrence after radical prostatectomy: long-term follow-up, BJU Int, vol.109, pp.32-41, 2012. ,
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, vol.280, pp.969-74, 1998. ,
Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials, Int J Radiat Oncol Biol Phys, vol.47, pp.609-624, 2000. ,
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials, J Urol, vol.176, issue.6, pp.16-20, 2006. ,
Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?, Int J Radiat Oncol Biol Phys, vol.83, pp.1141-1149, 2012. ,
The UCSF Cancer of the prostate risk assessment (CAPRA) score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy, J Urol, vol.173, pp.1938-1980, 2005. ,
Radical prostatectomy versus external beam radiotherapy for localized prostate cancer: comparison of treatment outcomes, Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al, 2014. ,
Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis, BJU Int, vol.111, pp.427-463, 2013. ,
Score for Prostate Cancer Risk, 2018. ,
, UCSF Department of Urology | Prostate Cancer Risk Assessment and the UCSF-CAPRA Score, 2018.
A multi-dimensional model of clinical utility, Int J Qual Health Care, vol.18, pp.377-82, 2006. ,
, R: a language and environment for statistical computing, Development Core Team R, 2010.
The digitize package: extracting numerical data from scatterplots, R J, vol.3, pp.25-31, 2011. ,
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Stat Med, vol.17, pp.2815-2849, 1998. ,
Meta-analysis in clinical trials, Control Clin Trials, vol.7, pp.177-88, 1986. ,
Bias in meta-analysis detected by a simple, graphical test, BMJ, vol.315, pp.629-663, 1997. ,
Quantifying heterogeneity in a meta-analysis, Stat Med, vol.21, pp.1539-58, 2002. ,
Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects, Stat Med, vol.33, pp.2521-2558, 2014. ,
A literature-based approach to evaluate the predictive capacity of a marker using time-dependent summary receiver operating characteristics, Stat Methods Med Res, vol.25, pp.674-85, 2016. ,
QALYs: the basics, Value Health, vol.12, pp.5-9, 2009. ,
A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients, Health Qual Life Outcomes, vol.16, p.40, 2018. ,
Optimal threshold estimator of a prognostic marker by maximizing a time-dependent expected utility function for a patient-centered stratified medicine, Stat Methods Med Res, vol.27, pp.1847-59, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02149057
Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-toevent outcome, BMC Med Res Methodol, vol.13, p.152, 2013. ,
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial, J Natl Cancer Inst, vol.100, pp.1144-54, 2008. ,
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, vol.11, pp.1066-73, 2010. ,
Short-term androgen suppression and radiotherapy versus intermediateterm androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial, Lancet Oncol, vol.15, pp.1076-89, 2014. ,
Tenyear follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, pp.2497-504, 2008. ,
The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer, BMC Health Serv Res, vol.14, p.163, 2014. ,
Three methods tested to model SF-6D health utilities for health states involving comorbidity/co-occurring conditions, J Clin Epidemiol, vol.63, pp.331-372, 2010. ,
Estimating health state utility values for comorbidities, PharmacoEconomics, vol.35, pp.89-94, 2017. ,
Health state utilities among contemporary prostate cancer patients on active surveillance, Transl Androl Urol, vol.7, pp.197-202, 2018. ,
A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Qual Life Res, vol.22, pp.2951-62, 2013. ,
Association between utility and treatment among patients with prostate cancer, Qual Life Res, vol.19, pp.711-731, 2010. ,
Estimating preferences for treatments in patients with localized prostate Cancer, Int J Radiat Oncol Biol Phys, 2014. ,
Utilities for prostate cancer health states in men aged 60 and older, Med Care, vol.43, pp.347-55, 2005. ,
Application of a 70-gene expression profile to Japanese breast Cancer patients, Breast Care Basel Switz, vol.10, pp.118-140, 2015. ,
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy, Cancer, vol.107, pp.2384-91, 2006. ,
Cancer of the prostate risk assessment) in Japanese patients receiving radical prostatectomy, Jpn J Clin Oncol, vol.41, pp.1259-64, 2011. ,
External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series, Urol Oncol, vol.30, pp.584-593, 2012. ,
Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients, J Urol, vol.178, pp.1957-62, 1962. ,
External validation of University of California, san Francisco, Cancer of the prostate risk assessment score, Urology, vol.72, pp.396-400, 2008. ,
Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the prostate risk assessment score: results from 2937 European patients, BJU Int, vol.110, pp.1714-1734, 2012. ,
Predictive value of the cancer of the prostate risk assessment score for recurrence-free survival after radical prostatectomy in Korea: a single-surgeon series, Korean J Urol, vol.55, pp.321-327, 2014. ,
Editorial comment to Japan Cancer of the prostate risk assessment for combined androgen blockade including bicalutamide: clinical application and validation, Int J Urol Off J Jpn Urol Assoc, vol.20, pp.714-719, 2013. ,
Comparative analysis of three risk assessment tools in Australian patients with prostate cancer, BJU Int, vol.108, issue.2, pp.51-57, 2011. ,
Development and internal validation of a prostate health index based nomogram for predicting prostate cancer at extended biopsy, J Urol, vol.188, pp.1144-50, 2012. ,
Closing the controversies gap in prostate cancer?, Nat Rev Clin Oncol, vol.11, p.299, 2014. ,
High-risk prostate cancer[mdash] classification and therapy, Nat Rev Clin Oncol, vol.11, pp.308-331, 2014. ,
Management of low risk prostate cancer-active surveillance and focal therapy, Nat Rev Clin Oncol, vol.11, pp.324-358, 2014. ,
Patient-reported outcomes after monitoring, surgery, or Radiotherapy for Prostate Cancer, N Engl J Med, 2016. ,
10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer, N Engl J Med, vol.375, pp.1415-1439, 2016. ,
Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak Int, J Soc Med Decis Mak, vol.26, pp.565-74, 2006. ,
Understanding the usefulness of prognostic models in clinical decision-making, J Physiother, vol.63, pp.121-126, 2017. ,
How do patients' treatment preferences compare with those of clinicians? Qual Health Care QHC, vol.10, pp.39-43, 2001. ,
Mind the gap: physicians' assessment of patients' importance weights in localized prostate cancer, PLoS One, vol.13, p.200780, 2018. ,
The strengths and limitations of meta-analyses based on aggregate data, BMC Med Res Methodol, vol.5, p.14, 2005. ,
The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy, Cancer, vol.117, pp.5039-5085, 2011. ,
The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models, Diagn Progn Res, vol.2, p.7, 2018. ,